Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection

Jennifer C. Price*, Eric C. Seaberg, John P. Phair, Mallory D. Witt, Susan L. Koletar, Chloe L. Thio

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

To determine the impact of highly active antiretroviral therapy (HAART) on liver disease, we analyzed changes in the aspartate aminotransferase to platelet ratio index (APRI) pre- and post-HAART initiation among 441 HIV-monoinfected and 53 HIV-viral hepatitis-coinfected men. Before HAART, APRI increased 17% and 34% among the HIV-monoinfected and coinfected men, respectively. With HAART initiation, APRI decreased significantly in men who achieved HIV RNA of <500 copies per milliliter: 16% for HIV-monoinfected and 22% for coinfected men. Decreases in APRI were dependent on HIV suppression. This protective effect of HAART decreased after 2 years, particularly in the HIV-monoinfected men.

Original languageEnglish (US)
Pages (from-to)319-323
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume72
Issue number3
DOIs
StatePublished - Jul 1 2016

Keywords

  • APRI
  • HBV
  • HCV
  • HIV
  • antiviral therapy
  • hepatitis
  • liver

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection'. Together they form a unique fingerprint.

  • Cite this